lutetium-177
Pre-clinical- Indications
- Cancer
Company intelligence / Profile preview
Nusano is a privately held physics and life sciences company focused on transforming the supply of medical radioisotopes. Its proprietary ion source enables efficient, high-yield production of over 40 different radioisotopes, supporting next-generation cancer diagnostics and therapies. The company's state-of-the-art facility in West Valley City, Utah will begin commercial-scale production in 2025 with key isotopes such as lutetium‑177 and actinium‑225. Nusano aims to address critical shortages in the global supply chain for medical isotopes essential to radiotherapeutics development.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nusano.